Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
Executive Summary
Express Scripts has agreed to give Praluent preferred access over Amgen's Repatha on its national formulary and is removing restrictions that have been a significant barrier to market access for the PCSK9 inhibitors.